Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

Abstract Background Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This is the final overall survival (OS) report from the...

Full description

Bibliographic Details
Published in:	BMC Medicine
Main Authors:	Ji-Youn Han, Myung-Ju Ahn, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, Na Mi Lee, Hyun Woo Jang, Heewon Han, Hyejoo Park, Jieon Lee, Byoung Chul Cho
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	ctDNA Lazertinib NSCLC TKI Overall survival
Online Access:	https://doi.org/10.1186/s12916-024-03620-8

Similar Items

Lazertinib‐Induced Rhabdomyolysis in a Patient With Non‐Small Cell Lung Cancer: A Case Report
by: Seunghun Lee, et al.
Published: (2025-02-01)

Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study
by: Mi‐Hyun Kim, et al.
Published: (2025-05-01)

Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer
by: Jeong Uk Lim, et al.
Published: (2024-07-01)

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations
by: Hui Zhang, et al.
Published: (2025-05-01)

Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control
by: Ha-Lim Jeon, et al.
Published: (2024-06-01)

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial
by: Bora Lee, et al.
Published: (2023-08-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer—A Narrative Review
by: Prabhat Gautam Roy, et al.
Published: (2025-08-01)

Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma
by: Taehee Kim, et al.
Published: (2019-12-01)

Severe scalp ulcerations and granulomata during treatment with amivantamab
by: Jingjia J Zhou, et al.
Published: (2024-03-01)

ctDNA as a novel and promising approach for cancer diagnosis
by: Negin Biglari, et al.
Published: (2023-08-01)

Quantification method of ctDNA using cell-free DNA methylation profile for noninvasive screening and monitoring of colon cancer
by: Hyojung Ryu, et al.
Published: (2024-07-01)

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks
by: Estelle Bourbon, et al.
Published: (2021-06-01)

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
by: Xinyue Wang, et al.
Published: (2025-04-01)

Circulating Tumor DNA (ctDNA) in Kidney Cancer: A Narrative Review
by: Wesley Yip, et al.
Published: (2023-07-01)

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
by: Xiaohong Han, et al.
Published: (2019-10-01)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer
by: Emily DeBortoli, et al.
Published: (2025-08-01)

Liquid Biopsy, ctDNA Diagnosis through NGS
by: Chen Lin, et al.
Published: (2021-08-01)

Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy
by: Xiaoling Wang, et al.
Published: (2024-01-01)

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker
by: Li Li, et al.
Published: (2023-12-01)

Real-World Technical Hurdles of ctDNA NGS Analysis: Lessons from Clinical Implementation
by: Simon Cabello-Aguilar, et al.
Published: (2025-09-01)

The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers
by: Ronan J. Kelly, et al.
Published: (2025-02-01)

Exploring the Clinical Value of Perioperative ctDNA‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma
by: Jimin Li, et al.
Published: (2025-02-01)

The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review)
by: Aleksandra Englisz, et al.
Published: (2025-05-01)

Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients
by: Mandy Radefeldt, et al.
Published: (2023-11-01)

Benchmarking UMI-aware and standard variant callers for low frequency ctDNA variant detection
by: Rugare Maruzani, et al.
Published: (2024-09-01)

Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
by: Fulong Wang, et al.
Published: (2023-12-01)

An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing
by: Xianyu Zhang, et al.
Published: (2025-06-01)

Clinical Utility of ctDNA Analysis in Lung Cancer—A Review
by: Kamil Makar, et al.
Published: (2025-06-01)

Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients
by: Valerio Gristina, et al.
Published: (2024-09-01)

Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
by: Michael E. Egger, et al.
Published: (2024-04-01)

Engineering of a DNA/γPNA Hybrid Nanoreporter for ctDNA Mutation Detection via γPNA Urinalysis
by: Zhichu Xiang, et al.
Published: (2024-09-01)

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
by: Lydia Warburton, et al.
Published: (2023-12-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
by: Joanne Chiu, et al.
Published: (2023-08-01)

Circulating tumor DNA (ctDNA) Detection via electrochemical Biosensing Tools
by: Sonya Sahin, et al.
Published: (2024-06-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment
by: Hussein Sabit, et al.
Published: (2025-03-01)

Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis
by: FAN Hao, et al.
Published: (2025-07-01)